Lv3
368 积分 2022-06-30 加入
A Real-World Single-Center Cohort Study on the Tolerability of Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
4天前
待确认
Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update
1个月前
已关闭
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
1个月前
已完结
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
1个月前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis
1个月前
已完结
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
1个月前
已完结
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma
1个月前
已完结
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
1个月前
已完结
皖公网安备34019202002308
